<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00374179</url>
  </required_header>
  <id_info>
    <org_study_id>CT-322.001</org_study_id>
    <nct_id>NCT00374179</nct_id>
  </id_info>
  <brief_title>CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase 1, Escalating Dose Study of CT-322, a VEGFR-2 Antagonist, as Monotherapy in Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adnexus, A Bristol-Myers Squibb R&amp;D Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adnexus, A Bristol-Myers Squibb R&amp;D Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: CT-322 may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping&#xD;
      blood flow to the cancer.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects of CT-322 in treating patients with&#xD;
      advanced solid tumors or non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of CT-322</measure>
    <time_frame>Throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics of CT-322 in these patients;</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to assess whether antibodies to this drug develop in these patients; and</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to make a preliminary assessment of the biological activity of CT-322 to alter tumor growth.</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">40</enrollment>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CT-322</intervention_name>
    <description>IV solution, weekly or bi-weekly</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS&#xD;
&#xD;
          -  Histologically proven advanced solid malignancy or NHL for which no standard therapy&#xD;
             exists or for which standard therapy had failed&#xD;
&#xD;
          -  No known brain or leptomeningeal disease&#xD;
&#xD;
          -  No prior bone marrow transplant or stem cell rescue&#xD;
&#xD;
          -  No histologically confirmed squamous non-small cell lung cancer (NSCLC) with central&#xD;
             chest tumor(s) still in place&#xD;
&#xD;
        PATIENT CHARACTERISTICS&#xD;
&#xD;
        Age:&#xD;
&#xD;
        * 18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
        * ECOG performance status ≤ 2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
        * &gt; 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  ANC ≥ 1500/mL&#xD;
&#xD;
          -  Platelets ≥ 100,000/mL&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL; and not requiring transfusion &gt; 1 unit/month&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 x ULN; if liver function abnormalities are due to the underlying&#xD;
             malignancy, then AST and ALT may be ≤ 5 x the ULN&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
          -  aPTT and PT &lt; 1.5 x ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine ≤ 1.5 x ULN; patients with serum creatinine &gt; 1 x ULN must also have&#xD;
             creatinine clearance (based on a 24-hour urine collection) ≤ 60 mL/min&#xD;
&#xD;
          -  No proteinuria &gt; 1+ on dipstick analysis; in the case of &gt; 1+ dipstick proteinuria, a&#xD;
             24-hour urine collection for protein must be &lt; 500 mg/24 hours&#xD;
&#xD;
          -  Urinary protein/creatinine ratio &lt; 1&#xD;
&#xD;
          -  No glomerulonephritis&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction,&#xD;
             unstable angina, symptomatic congestive heart failure, severe uncontrolled&#xD;
             hypertension, hemorrhagic or thrombotic stroke or any other CNS bleeding within the&#xD;
             preceding 12 months&#xD;
&#xD;
          -  LVEF normal by echocardiogram or MUGA within the past 12 months if there was prior&#xD;
             exposure to anthracyclines or radiotherapy encompassing the heart&#xD;
&#xD;
        Immunologic:&#xD;
&#xD;
        * Not known to have human immunodeficiency virus (HIV), active hepatitis virus C (HVC), or&#xD;
        active hepatitis virus B (HVB)&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Negative pregnancy test within 7 days prior to enrollment&#xD;
&#xD;
          -  Not pregnant or breast feeding&#xD;
&#xD;
          -  Fertile patients must agree to use effective contraception or commit to abstinence&#xD;
             during the study period, or be surgically sterile&#xD;
&#xD;
          -  No serious nonhealing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  Have the ability to understand and sign an informed consent document&#xD;
&#xD;
          -  Be willing and able to comply with scheduled visits, treatment plan, laboratory tests,&#xD;
             and other study procedures&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior biological or immunotherapy and recovered&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy and recovered&#xD;
&#xD;
          -  At least 6 weeks for mitomycin C and nitrosoureas prior to study entry and recovered&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
        * At least 4 weeks since prior radiotherapy to a visceral organ and recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 4 weeks since prior major or laparoscopic surgery and recovered&#xD;
&#xD;
          -  At least 1 week since prior minor surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  Not concurrently enrolled in another therapeutic clinical trial involving ongoing&#xD;
             therapy&#xD;
&#xD;
          -  No concurrent full dose, therapeutic anti-coagulation with warfarin or related oral&#xD;
             anti-coagulants or unfractionated or low molecular weight heparins; low dose warfarin&#xD;
             for catheter prophylaxis or acetylsalicylic acid ≤ 325 mg/day is acceptable&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Drug Development</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78245-3217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>September 8, 2006</study_first_submitted>
  <study_first_submitted_qc>September 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2006</study_first_posted>
  <last_update_submitted>February 23, 2009</last_update_submitted>
  <last_update_submitted_qc>February 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Director, Adnexus, A Bristol-Myers Squibb R&amp;D Company</name_title>
    <organization>Adnexus, A Bristol-Myers Squibb R&amp;D Company</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

